Bristol-Myers Squibb Company (BMY) Stake Lifted by Flagship Harbor Advisors LLC
Flagship Harbor Advisors LLC lifted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 37.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,370 shares of the biopharmaceutical company’s stock after acquiring an additional 3,633 shares during the period. Flagship Harbor Advisors LLC’s holdings in Bristol-Myers Squibb were worth $707,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Jennison Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after acquiring an additional 178,436 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares during the period. Legal & General Group Plc lifted its holdings in shares of Bristol-Myers Squibb by 4.3% during the 1st quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after acquiring an additional 335,795 shares during the period. Finally, Swiss National Bank lifted its holdings in shares of Bristol-Myers Squibb by 27.2% during the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares during the period. Institutional investors and hedge funds own 68.80% of the company’s stock.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) traded up 0.27% during trading on Tuesday, reaching $62.89. The company had a trading volume of 2,192,380 shares. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.47. The company has a 50 day moving average of $57.59 and a 200-day moving average of $55.71. The firm has a market capitalization of $103.13 billion, a P/E ratio of 22.97 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm posted $0.69 earnings per share. The company’s quarterly revenue was up 5.6% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
Several research analysts recently commented on BMY shares. Jefferies Group LLC restated a “buy” rating and issued a $66.00 price target on shares of Bristol-Myers Squibb in a report on Monday. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price objective on the stock in a research note on Wednesday, July 12th. Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long” rating to a “term buy” rating in a research note on Tuesday. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, BMO Capital Markets reiterated an “underperform” rating and set a $47.00 price objective (down previously from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $62.54.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.